Human Genome Sciences Inc. Updates Albuferon Data

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

U.S. Centers for Disease Control and Prevention • Medical News

Human Genome Sciences Inc. Updates Albuferon Data

May 3, 2006

On Monday, Human Genome Sciences Inc. said a mid-stage drug trial of patients who had been previously treated for hepatitis C found that its candidate Albuferon, in combination with ribavirin, reduced the virus to undetectable levels in 31 percent (22 of 71 patients) of patients treated for 48 weeks. Twelve weeks after treatment ended, 20 percent (14 patients) maintained undetectable levels of virus. HGS plans to enter more advanced clinical trials by the end of this year.

Back to other news for May 3, 2006

Search the Newsroom archive

Excerpted from:
Associated Press
05.01.06

This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.